# Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia

Study · id `cardio:ct-nct06834490` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06834490](<https://clinicaltrials.gov/study/NCT06834490>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06834490

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 318 participants.

## Technical summary

Registry record NCT06834490. Randomized; double masking; primary purpose treatment. Start 2019-11-05 (actual); primary completion 2020-12-08 (actual). Results posted on 2025-10-06.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 318 participants (enrolled count; ClinicalTrials.gov record NCT06834490, source copy `cardio:ctgov-nct06834490-2025-10-06`, retrieved 2026-10-26)
- Started: 2019-11-05 (actual) (ClinicalTrials.gov record NCT06834490, source copy `cardio:ctgov-nct06834490-2025-10-06`, retrieved 2026-10-26)
- Primary completion: 2020-12-08 (actual) (ClinicalTrials.gov record NCT06834490, source copy `cardio:ctgov-nct06834490-2025-10-06`, retrieved 2026-10-26)
- Completion: 2020-12-08 (actual) (ClinicalTrials.gov record NCT06834490, source copy `cardio:ctgov-nct06834490-2025-10-06`, retrieved 2026-10-26)
- Results first posted: 2025-10-06 (ClinicalTrials.gov record NCT06834490, source copy `cardio:ctgov-nct06834490-2025-10-06`, retrieved 2026-10-26)
- Countries: Russia; Uzbekistan (ClinicalTrials.gov record NCT06834490, source copy `cardio:ctgov-nct06834490-2025-10-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06834490-2025-10-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia
- Acronym: MEMO
- Condition: Chronic Cerebral Ischemia
- Intervention (Drug): Mexidol
- Intervention (Drug): Placebo
- Lead sponsor: Pharmasoft
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Pharmasoft (`cardio:org-pharmasoft`)

## Provenance

Content hash: 30fa6d42cb00620d4b97339bc37d7755891540d052ad3a67b1e1a19022bb3f2a
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
